By using DiabetesTimes.co.uk, you agree to our terms and use of cookies to enhance your experience.

SGLT-2 inhibitor backed by NICE for treating Type 2 diabetes

By Editor
9th April 2015
Latest news, NICE Pharmaceutical

A new treatment for Type 2 diabetes has been recommended for the NHS by health watchdog NICE.

Empagliflozin, also known as Jardiance, has been recommended as a treatment for Type 2 diabetes when taken with metformin, only if the person:
• Cannot take a type of drug called a sulfonylurea or
• Is at significant risk of hypoglycaemia or its consequences.

If they need to take three ‘antidiabetic’ drugs, empagliflozin is recommended as a treatment for Type 2 diabetes when taken with either metformin and a sulfonylurea, or with metformin and a type of drug called a thiazolidinedione.Empagliflozin is also recommended as a treatment for Type 2 diabetes when taken with insulin, with or without other antidiabetic drugs.

Empagliflozin should be available on the NHS within three months of the guidance being issued

A spokesman for NICE said: “If you have Type 2 diabetes and your doctor thinks that empagliflozin, as described above, is the right treatment, you should be able to have the treatment on the NHS.

“Empagliflozin should be available on the NHS within three months of the guidance being issued. If you are not eligible for treatment as described above, you should be able to continue taking empagliflozin until you and your doctor decide it is the right time to stop.”

To read the NICE technology appraisal guidance, which made the recommendation, click here.

Comments (0)

Register an account or login to comment